Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Brief Summary: The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth of tumors) of patients with relapsed EGFRvIII positive glioblastoma.


Options:
A: Arm Label: Carbon Ion Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Carbon Ion Radiotherapy | Arm Label: Standard Treatment: Fractionated Stereotacitc Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Fractionated Stereotactic Radiotherapy (FSRT) | Intervention Type: RADIATION; Name: Carbon Ion Radiotherapy; Assigned to Arm(s): Carbon Ion Radiotherapy | Intervention Type: RADIATION; Name: Fractionated Stereotactic Radiotherapy (FSRT); Assigned to Arm(s): Standard Treatment: Fractionated Stereotacitc Radiotherapy
B: Arm Label: Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Rindopepimut (CDX-110) with GM-CSF | Arm Label: Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: KLH | Arm Label: Group 2 and 2C: Refractory to Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Rindopepimut (CDX-110) with GM-CSF | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut., Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control, Group 2 and 2C: Refractory to Bevacizumab | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut., Group 2 and 2C: Refractory to Bevacizumab | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control
C: Arm Label: First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Lomustine, Radiation: Radiotherapy, Drug: Temozolomide, Drug: SOC Agent | Arm Label: First-Line Bevacizumab followed by Placebo + Lomustine/SOC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Lomustine, Drug: Placebo, Radiation: Radiotherapy, Drug: Temozolomide, Drug: SOC Agent | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: DRUG; Name: Lomustine; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: DRUG; Name: SOC Agent; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC
D: Arm Label: Calibration Arm; Type: EXPERIMENTAL; Interventions: Drug: fotemustine | Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab [Avastin] | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: fotemustine; Assigned to Arm(s): Calibration Arm

Answer: B